News & Events about Repare Therapeutics Inc.
Repare Therapeutics (NASDAQ:RPTX Get Rating) was upgraded by Stifel Nicolaus from a hold rating to a buy rating in a note issued to investors on Friday, The Fly reports. The brokerage currently has a $16.00 price target on the stock, up from their previous price ...
Repare Therapeutics (NASDAQ:RPTX Get Rating) had its target price upped by equities researchers at HC Wainwright from $25.00 to $26.00 in a research report issued to clients and investors on Friday, The Fly reports. HC Wainwrights price objective points to a potential upside of 116.31% from the ...
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small...
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (Repare or the Company) (NASDAQ: RPTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX PR Newswire NEW YORK, Feb. 13, 2023 NEW YORK, Feb. 13, 2023...